TobaccoReporter logo

Tag: Zyn

  • PMI U.S. Opens $1.2 Billion Colorado Manufacturing Campus

    PMI U.S. Opens $1.2 Billion Colorado Manufacturing Campus

    Philip Morris International’s U.S. businesses announced the official opening of its $1.2 billion manufacturing campus in Aurora, Colorado, expanding domestic production capacity for Zyn nicotine pouches and strengthening the company’s U.S. supply chain and export capabilities. The 780,000-square-foot facility, located on a 148-acre site, began full commercial production in July 2026 and represents PMI U.S.’s first greenfield manufacturing complex in the United States. The campus integrates production, packaging, warehousing, distribution, and operations, and will support markets across Asia, Latin America, and the Caribbean.

    The investment, originally announced as a $600 million project in 2024, doubled in planned capital expenditures through 2028, including manufacturing equipment, infrastructure, facility development, and future production expansion. “Aurora represents an important milestone for PMI U.S. and our continued investment in our business here,” said Stacey Kennedy, CEO of PMI U.S. “This facility expands our production capacity, strengthens our supply chain, and enhances our ability to serve growing demand in the United States and around the world.”

    The facility is expected to directly employ approximately 500 people and contribute to broader economic activity in Colorado, with PMI estimating the site will support around 1,000 indirect jobs.

  • Smoke-Free Gains Push PMI Over $11B in Q2

    Smoke-Free Gains Push PMI Over $11B in Q2

    Philip Morris International reported strong second-quarter 2026 results, with net revenues exceeding $11 billion for the first time as smoke-free products drove growth. Reported diluted EPS fell 7.7% to $1.80 due to a $511 million non-cash impairment charge tied to PMI’s Rothmans, Benson & Hedges investment, while adjusted diluted EPS rose 15.2% to $2.20, or 13.6% excluding currency. Shipments increased 2.5%, led by a 7.5% rise in smoke-free products. Net revenues grew 10.4% to $11.2 billion, with smoke-free products representing about 42% of sales, while operating income increased 22% to $4.5 billion.

    The international smoke-free business remained PMI’s main growth driver, with revenue up 14.2% and volumes rising 8%. IQOS heat-not-burn shipments increased 7.6%, maintaining PMI’s leading position in the category, while growth continued across Europe and other key markets despite challenges from Japan’s excise increase and Poland’s flavor restrictions. PMI said it would increase investment in Zyn as the nicotine pouch volumes expanded globally, with the brand now available in 60 markets, while VEEV e-vapor shipments rose 55.1% as PMI continued expanding its smoke-free portfolio.

    International combustible sales also grew, supported by pricing and market gains, while the U.S. business remained under pressure. Combustible revenue increased 9.8%, with cigarette growth in Turkey, Indonesia, and Egypt, while Marlboro gained market share. U.S. revenue declined 0.7% due to weakness in cigars and wellness products, though Zyn shipments rose 1.8% to 2.9 billion pouches following portfolio expansions. PMI maintained its 2026 outlook, forecasting adjusted EPS growth of 9.5% to 11.5%, organic revenue growth of 5% to 7%, and continued investment in smoke-free products.

    According to Reuters, PMI’s shares rose ​about 5% in early trading even though the company also cut its annual profit ​forecast for the third time this year due to negative currency effects.

  • Former CTP Toxicologist Accuses FDA of Approving Zyn Without Full Facts

    Former CTP Toxicologist Accuses FDA of Approving Zyn Without Full Facts

    A report published yesterday (July 14) by The Examination and STAT raised questions about the U.S. Food and Drug Administration’s review process for Philip Morris International’s Zyn nicotine pouches, alleging that agency scientists had unresolved concerns about the composition and potential health implications of the pouch material before the product was authorized for sale. The report said FDA toxicologist Christy Leppanen questioned whether regulators had adequately assessed possible microplastic exposure after conducting informal tests that found Zyn pouches did not dissolve when exposed to saliva or other conditions. Leppanen alleged that the FDA did not seek additional information from PMI about the pouch material before approving the product, while former FDA officials cited in the report questioned whether the agency fully evaluated all product components as required under federal law.

    The allegations come as nicotine pouches have become one of the fastest-growing segments of the tobacco and nicotine market. The U.S. nicotine pouch market is estimated to grow 37% in 2026 to $6.8 billion, according to TobaccoIntelligence, with companies promoting pouches as lower-risk alternatives to combustible cigarettes because they deliver nicotine without smoke exposure. The FDA has authorized certain nicotine pouches, including Zyn, based on a review of whether the products are appropriate for the protection of public health, weighing potential risks such as youth uptake against potential benefits for adult smokers transitioning away from cigarettes. PMI defended the authorization process, citing the FDA’s scientific review, while the FDA said its evaluation did not identify additional concerns regarding the ingredients or materials used in Zyn products. Concerns raised by Leppanen and other scientists center on whether pouch materials could release microscopic particles during use and what long-term effects those exposures may have. The FDA’s recent decision allowing PMI to communicate that Zyn use instead of cigarettes lowers the risk of certain smoking-related diseases represented a major regulatory milestone for the category, but, according to The Examination, the allegations in the report may fuel additional debate over product standards, disclosure requirements, and the depth of scientific reviews for emerging nicotine products.

  • CAPHRA Says FDA’s Pouch Pivot Should Trigger Policy Rethink 

    CAPHRA Says FDA’s Pouch Pivot Should Trigger Policy Rethink 

    The Coalition of Asia Pacific Tobacco Harm Reduction Advocates is urging governments across the Asia-Pacific region to review the U.S. Food and Drug Administration’s recent authorization allowing 20 Zyn nicotine pouch products to carry reduced-risk claims for adult smokers. CAPHRA said the FDA’s decision recognizes the principle of relative risk following scientific review and should encourage regulators to distinguish between combustible cigarettes, high-risk smokeless tobacco products, and lower-risk smoke-free nicotine alternatives.

    The group called on policymakers to adopt evidence-based, risk-proportionate regulation, strengthen youth access restrictions and product standards, and ensure adult consumers receive accurate information about the comparative risks of nicotine products, arguing that treating all nicotine products as equally harmful undermines public health objectives.

  • FDA Issues MRTP Orders for 20 Zyn Products

    FDA Issues MRTP Orders for 20 Zyn Products

    The U.S. Food and Drug Administration issued Modified Risk Tobacco Product orders for 20 Zyn nicotine pouch products manufactured by Swedish Match USA, making Zyn the first nicotine pouch brand authorized to market reduced-risk claims compared with cigarettes. The FDA-authorized claim states that using Zyn instead of cigarettes lowers the risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis. The authorization applies to 10 Zyn flavors in both 3 mg and 6 mg nicotine strengths and builds on the products’ January 2025 authorization for sale through the FDA’s premarket tobacco product application pathway.

    The FDA said its decision followed an extensive scientific review of the products’ relative health risks, consumer understanding of the claim, youth use data, and overall population health impact. The agency concluded that the modified-risk claim is scientifically supported, that consumers understand its meaning, and that allowing the claim is expected to benefit public health. The authorization requires Swedish Match USA to conduct post-market surveillance and behavioral studies, and the orders will expire after five years unless renewed. The FDA also noted it retains the authority to withdraw the orders if continued marketing no longer benefits public health, including if youth uptake increases.

    Separately, Philip Morris International said the decision expands its portfolio of FDA-authorized modified-risk products, which also includes IQOS heated tobacco products and General snus. PMI U.S. CEO Stacey Kennedy said the authorization provides adult nicotine consumers with FDA-reviewed, science-based information about the health benefits of switching completely from cigarettes to Zyn.

  • Haypp Announces Zyn Ultra Launch Across U.S.  

    Haypp Announces Zyn Ultra Launch Across U.S.  

    Haypp Group announced that Zyn Ultra nicotine pouches are available through its U.S. online retailers, Nicokick.com and Northerner.com, as of June 15. The new Zyn format contains 20 pouches per can, compared with 15 in the flagship lineup, and will initially launch in 9 mg strength across eight flavors, with an 11 mg range scheduled to follow later in June. Haypp said the rollout expands its portfolio of more than 300 nicotine pouch products and follows the resumption of direct-supplied Zyn sales in the U.S. in September 2025.

  • Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada Issues Recall for Zyn, Siberia Pouches

    Health Canada issued a nationwide recall for Siberia and ZYN nicotine pouches last week, saying the products are being sold without market authorization. The recall covers Siberia 35 mg pouches and Zyn 6 mg varieties across multiple flavors and all lots, with officials classifying it as a Type II risk, meaning potential temporary health effects but low likelihood of serious harm.

    Consumers are advised to check whether their products are affected, contact their healthcare provider before stopping use, and report any adverse effects or safety concerns to Health Canada, which is also directing users to the recalling firm for further information.

  • Zyn Expanding Flavors in the Philippines

    Zyn Expanding Flavors in the Philippines

    Philip Morris International expanded its Zyn nicotine pouch portfolio in the Philippines with the introduction of new variants, including Cool Breeze in a 1.5mg strength and the Tropical flavor in 3mg and 6mg strengths. The update broadens the brand’s existing strength architecture in the market, which now spans 1.5mg, 3mg and 6mg across multiple flavors listed on its official Philippines website.

    According to the company, the 1.5mg Cool Breeze variant is positioned as a lower-strength option aimed at adult nicotine consumers who are new to nicotine pouches, while higher strengths will continue to serve existing users. The Tropical flavor is currently available in 3mg and 6mg formats, further expanding ZYN’s flavor range in the Philippines.

    The Philippine portfolio also includes several flavors such as Fresh Breeze, Dark Purple, and Espressino across different nicotine strengths.

  • PMI to Present at the dbAccess Global Consumer Conference

    PMI to Present at the dbAccess Global Consumer Conference

    Philip Morris International Inc. said it will host a live webcast of remarks and a Q&A session with CEO Jacek Olczak at the 2026 dbAccess Global Consumer Conference on June 2, at 11:15 a.m. CET. The session will be streamed live and made available for replay for one year via the company’s investor relations channels, including its mobile app and website.

    The event will provide an update on PMI’s strategy as it continues to position itself as a “smoke-free” consumer goods company, with a portfolio spanning cigarettes and reduced-risk products such as heat-not-burn devices, nicotine pouches, and e-vapor products. The company also highlighted ongoing regulatory milestones, including U.S. FDA authorizations for products such as Zyn nicotine pouches and IQOS devices, as it continues to expand its investor communications around its long-term transition strategy.

  • Tobacco-Free Kids Launches Campaign to End F1’s Tobacco Ties

    Tobacco-Free Kids Launches Campaign to End F1’s Tobacco Ties

    Today (March 28), the Campaign for Tobacco-Free Kids launched a new advertising initiative, “End the Formula,” ahead of the May 3 Miami Grand Prix, calling on Formula 1 to eliminate all tobacco-related sponsorships. The campaign targets partnerships between major F1 teams and companies, including Philip Morris International and British American Tobacco, which promote nicotine pouch and e-cigarette brands such as Zyn, Velo, and Vuse through branding on cars, driver apparel, and digital media. The campaign ties into similar efforts that began in March, which included ads, coordinated outreach with 162 organizations across 57 countries, and more than 25,000 petition messages urging F1 and affiliated partners to end these sponsorship arrangements.